YAbS







Panitumumab Approved Naked monospecific

Antibody Information

Entry ID 7
INN Panitumumab
Status Approved
Drug code(s) ABX-EGF
Brand name Vectibix
mAb sequence source mAb human
General Molecular Category Naked monospecific
Format, general category Full length Ab
Format details None
Isotype (Fc) IgG2
Light chain isotype kappa
Linker None
Ave. DAR None
Conjugated/fused moiety None
Discovery method/technology Transgenic mouse (Xenomouse)

Therapeutic information

Target(s) EGFR
Indications of clinical studies Renal, prostate, lung, breast, colorectal Cancers
Primary therapeutic area Cancer

Development stage information

Phase lengths*
*The graph represents early-stage clinical development phase lengths. For molecules approved or under evaluation for marketing authorization in the US is provided a complete overview of all clinical development phase lengths. Phase lengths are calculated from the start of the first in human (FIH) study (Start of clinical phase). “Start of Phase 2” bar represents Phase 1 length (Start of clinical phase to start of Phase 2); “Start of Phase 3” bar represents Phase 1+2 length (Start of clinical phase to start of Phase 3); “Date BLA/NDA submitted” bar represents Phase 1+2+3 length (Start of clinical phase to Date BLA/NDA submitted); and “Date of first US approval” bar represents Phase 1 to first US approval length (Start of clinical phase to Date of first US approval).
Most advanced stage of development (global) Approved EU, US, Japan, Australia
Status Active
Start of clinical phase (IND filing or first Phase 1) July 19, 1999
Start of Phase 2 April 15, 2001
Start of Phase 3
Date BLA/NDA submitted to FDA March 29, 2006
Year of first approval (global) 2006
Date of first US approval September 27, 2006
INN, US product name Panitumumab
US or EU approved indications Colorectal cancer

Company information

Company Abgenix
Licensee/Partner None
Comments about company or candidate None
Full address of company 6701 Kaiser Drive Fremont, CA 94555 United States
North America
United States of America
https://pitchbook.com/profiles/company/40732-21#overview

Description/comment

None

Additional information

Anticipated events None
Factor(s) contributing to discontinuation None